MA27784A1 - Mediateurs de cytokine 1-2-dihydropyrazol-3-ones - Google Patents

Mediateurs de cytokine 1-2-dihydropyrazol-3-ones

Info

Publication number
MA27784A1
MA27784A1 MA27850A MA27850A MA27784A1 MA 27784 A1 MA27784 A1 MA 27784A1 MA 27850 A MA27850 A MA 27850A MA 27850 A MA27850 A MA 27850A MA 27784 A1 MA27784 A1 MA 27784A1
Authority
MA
Morocco
Prior art keywords
group
dihydropyrazol
ones
michael
compounds
Prior art date
Application number
MA27850A
Other languages
English (en)
Inventor
Matthew John Laufersweiler
Michael Philip Clark
Biswanath De
Cynthia Monesa Crago
Jane Far-Jine Djung
Michael George Natchus
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MA27784A1 publication Critical patent/MA27784A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

" 1,2-DIHYDROPYRAZOL-3-ONES EN TANT QUE MEDIATEURS DE CYTOKINE " Invention de : LAUFERSWEILER, Matthew, Joha CRAGO, Cynthia, Monesa CLARK, Michael, Philip DJUNG, Jane, Far-Jine DE, Biswanath NATCHUS, Michael, George Priorité : demande de brevet déposée le 19 mars 2002 sous le No. La présente invention concerne des composés qui sont capables de prévenir la libération extracellulaire de cytokines inflammatoires, lesdits composés, ou leurs formes énantiomères et diastéréomères, ou leurs sels pharmaceutiquement acceptables, répondant à la formule (A) dans laquelle R est un motif éther ou amino, R1 est un groupe phényle substitué, chacun des motifs R2 et R3 est choisi indépendamment dans le groupe constitué par : a) l'hydrogène ; et b) un groupe hydrocarbyle en C1 à C10 substitué ou non substitué, choisi dans le groupe constitué par : i) un groupe alkyle en C1 à C10 linéaire, ramifié ou cyclique ; ii) un groupe aryle en C1 à C10 ; iii) un groupe hétérocyclique en C1 à C10 ; iv) un groupe hétéroaryle en C1 à C10.
MA27850A 2002-03-19 2004-09-09 Mediateurs de cytokine 1-2-dihydropyrazol-3-ones MA27784A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36570102P 2002-03-19 2002-03-19

Publications (1)

Publication Number Publication Date
MA27784A1 true MA27784A1 (fr) 2006-03-01

Family

ID=28454704

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27850A MA27784A1 (fr) 2002-03-19 2004-09-09 Mediateurs de cytokine 1-2-dihydropyrazol-3-ones

Country Status (22)

Country Link
US (1) US6677337B2 (fr)
EP (1) EP1485167A1 (fr)
JP (1) JP2006502093A (fr)
KR (1) KR20040093158A (fr)
CN (1) CN1642600A (fr)
AR (1) AR039001A1 (fr)
AU (1) AU2003220216A1 (fr)
BR (1) BR0308579A (fr)
CA (1) CA2477091A1 (fr)
CO (1) CO5611175A2 (fr)
IL (1) IL163712A0 (fr)
MA (1) MA27784A1 (fr)
MX (1) MXPA04009088A (fr)
MY (1) MY134226A (fr)
NO (1) NO20044413L (fr)
NZ (1) NZ534869A (fr)
PE (1) PE20040160A1 (fr)
PL (1) PL372882A1 (fr)
RU (1) RU2004130843A (fr)
TW (1) TW200306182A (fr)
WO (1) WO2003080184A1 (fr)
ZA (1) ZA200407135B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473695B2 (en) * 2001-10-22 2009-01-06 Mitsubishi Tanabe Pharma Corporation 4-imidazolin-2-one compounds
CA2497007A1 (fr) * 2002-09-09 2004-03-18 Amgen Inc. Derives de 1, 4, 5-substitue 1, 2-dihydro-pyrazol-3-one et 3-alcoxy-1h-pyrazole, tnf-alpha et agents reduisant l'interleukine dans le traitement des inflammations
US7482356B2 (en) * 2003-11-10 2009-01-27 The Procter & Gamble Company Bicyclic pyrazolone cytokine inhibitors
KR20070086188A (ko) * 2004-11-17 2007-08-27 미카나 테라퓨틱스, 인크. 키나제 억제제
AU2006279794B2 (en) * 2005-08-12 2011-04-07 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
BRPI0616630B8 (pt) * 2005-09-30 2021-05-25 Miikana Therapeutics Inc compostos de pirazol substituídos
JP2010529193A (ja) * 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
WO2018192793A1 (fr) 2017-04-20 2018-10-25 Basf Se Dérivés de rhodanine substitués

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663327A (en) * 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
EP1343781B1 (fr) * 2000-12-05 2008-09-03 Vertex Pharmaceuticals Incorporated Inhibiteurs de kinases c-jun n-terminales (jnk) et d'autres proteines kinases
AU2002308748A1 (en) * 2001-05-16 2002-11-25 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
US6566357B1 (en) * 2001-09-20 2003-05-20 The Procter & Gamble Co. Spirocyclic-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

Also Published As

Publication number Publication date
AR039001A1 (es) 2005-02-02
RU2004130843A (ru) 2005-08-27
US20030225082A1 (en) 2003-12-04
JP2006502093A (ja) 2006-01-19
EP1485167A1 (fr) 2004-12-15
PE20040160A1 (es) 2004-04-30
US6677337B2 (en) 2004-01-13
CA2477091A1 (fr) 2003-10-02
NZ534869A (en) 2006-09-29
WO2003080184A1 (fr) 2003-10-02
CN1642600A (zh) 2005-07-20
MXPA04009088A (es) 2004-12-06
CO5611175A2 (es) 2006-02-28
BR0308579A (pt) 2005-01-25
IL163712A0 (en) 2005-12-18
MY134226A (en) 2007-11-30
TW200306182A (en) 2003-11-16
NO20044413L (no) 2004-10-18
KR20040093158A (ko) 2004-11-04
PL372882A1 (en) 2005-08-08
ZA200407135B (en) 2005-09-21
AU2003220216A1 (en) 2003-10-08

Similar Documents

Publication Publication Date Title
KR910009684A (ko) 방향족 아민 화합물, 이의 제조방법 및 이들의 존재하는 약제학적 조성물
RU2371433C2 (ru) Фенилзамещенные пирролидоны
RU2196769C2 (ru) Производные аминобензойной кислоты, фармацевтическая композиция
DK0915866T3 (da) Forbedret fremgangsmåde til syntese af beskyttende estere af (S)-3,4-dihydroxysmørsyre
ES2190396T3 (es) Nuevos compuestos amino-triazoles, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ATE306261T1 (de) Antithrombosemittel
NO20054032L (no) Glykolipidderivater, fremgangsmate for fremstilling derav, mellomprodukter for fremstilling derav oq fremgangsmater for fremstilling av mellomproduktene.
JP2008511601A5 (fr)
RU2005105564A (ru) Производные бензимидазола и их применение в качестве пролекарств ингибиторов протонного насоса
TNSN07178A1 (fr) N-sulfonylaminobenzyl-2-phenoxy-acetamides substitues
MA27784A1 (fr) Mediateurs de cytokine 1-2-dihydropyrazol-3-ones
HRP20140988T1 (hr) Derivati 6-supstituirane fenoksikromankarboksilne kiseline
MA27197A1 (fr) Sels de tolterodine
MA31674B1 (fr) Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique
MA27593A1 (fr) Derives de n-acyle piperidine utilises comme ligands du recepteur de la melanocortine dans le traitement de troubles de l'alimentation.
DK1157998T3 (da) Heterocykliske forbindelser, mellemprodukter derfor og elastaseinhibitorer
MA27066A1 (fr) 6,7-DIHYDRO-5H-PYRAZOLO[1,2-A]PYRAZOL-1-ONES CONTRôLANT LES CYTOKINES INFLAMMATOIRES.
HUP0303279A2 (hu) Indolo-pirrolo-karbazolok cukorszármazékai, mint topoizomeráz inhibitorok és ezeket tartalmazó gyógyszerkészítmények
MA27795A1 (fr) Derives d'amine cycliques, procedes de preparation de ceux-ci et compositions pharmaceutiques les contenant
CA2519110A1 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation dans le traitement de la douleur
EA200600570A1 (ru) Замещенные 2-карбониламино-6-пиперидинаминопиридины и замещенные 1-карбониламино-3-пиперидинаминобензолы как агонисты 5-ht
TR200001239T2 (tr) Tiyazolidinediyon türevlerini hazırlama prosesi.
ATE308540T1 (de) Antithrombosemittel
AR035765A1 (es) Composiciones fungicidas de n-2-piridinilmetilbenzamida y del propil ester de acido (3-(dimetilamino)-propil) carbamico; procedimientos curativos o preventivos contra hongos fitopatogenos de cultivos, utilizando dichas composiciones y productos de aplicacion combinada, simultanea, separada o secuenc
Biel et al. Bronchodilators, N-Substituted Derivatives of 1-(3', 4'-Dihydroxyphenyl)-2-aminoethanol (Arterenol)